ID1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of human A-549 cells carrying a targeted disruption of the ID1 gene. This heterogeneous knockout pool serves as a robust loss-of-function model for investigating ID1-dependent phenotypes in a lung adenocarcinoma background. Without clonal isolation, the polyclonal format captures a range of editing events, enabling functional studies that reflect the diversity of ID1 inactivation commonly encountered in pooled screening and population-based assays. The product is ideal for researchers seeking to interrogate the role of ID1 as a dominant-negative regulator of basic helix-loop-helix (bHLH) transcription factors in non-small cell lung carcinoma (NSCLC).
The host A-549 cell line is a well-established human lung adenocarcinoma epithelial model, originally derived from a type II pneumocyte tumor. It serves as a standard in vitro system for NSCLC research, retaining key features such as oncogenic KRAS mutation and aberrant signaling through pathways commonly dysregulated in lung cancer. A-549 cells exhibit epithelial morphology and are widely employed to study tumor cell proliferation, epithelial-mesenchymal transition (EMT), metastasis, and drug responses. Their robust growth and genetic tractability make them an appropriate chassis for CRISPR-mediated genome editing, allowing straightforward examination of gene function in a clinically relevant context.
At the molecular level, ID1 functions by sequestering ubiquitously expressed E proteins??TCF3 (E2A), TCF12 (HEB), and TCF4 (E2-2)??into non-functional heterodimers, thereby blocking bHLH transcription factors from activating target genes involved in differentiation and cell cycle arrest. Upstream signals, including TGF-??1, BMP4, BMP7, EGF, and FGF2, converge on SMAD, MAPK/ERK, and PI3K/AKT pathways to drive ID1 expression. In turn, ID1 represses cyclin-dependent kinase inhibitors p16INK4a and p21CIP1, upregulates Cyclin D1 for cell cycle progression, and modulates apoptosis via Bcl-2. Additionally, ID1 promotes invasive and angiogenic processes through transcriptional regulation of MMP2 and VEGFA. Disruption of ID1 in this polyclonal knockout pool relieves the dominant-negative block, permitting bHLH factors to activate programs that restrain proliferation and promote apoptosis.
In the A-549 NSCLC context, ID1 is frequently overexpressed and associated with enhanced tumorigenicity, resistance to apoptosis, and EMT-driven metastatic features. CRISPR/Cas9-mediated gene disruption in this polyclonal population creates a versatile platform to dissect how loss of ID1 alters oncogenic signaling networks. Because the knockout is introduced across a population, the model captures heterogeneous editing outcomes, mimicking the variable ID1 expression observed in tumors and providing a powerful tool for phenotype discovery and drug response studies without the bias of single-clone selection.
This ID1 knockout cell product supports diverse experimental applications, including Western blotting and RT-qPCR to confirm ID1 depletion and probe downstream effectors; cell viability (MTT/CCK8), colony formation, and migration/invasion assays to evaluate proliferation and metastatic potential; flow cytometry for apoptosis and cell cycle distribution; and transcriptome-wide RNA-seq to map ID1-regulated networks. Interaction studies with E proteins can be performed via co-immunoprecipitation, while luciferase reporter assays enable quantification of bHLH transcriptional activity. Phospho-signaling analyses (e.g., ERK1/2, AKT, SMAD1/5/8) further elucidate crosstalk with upstream pathways. For further technical details or customization, please contact Ascent Research.
